Skip to content
octaplas
Main Menu
  • Intended for US Healthcare Professionals Only
  • Important Safety Information
  • Full Prescribing Information
  • Contact Us
  • Search Close
  • What is octaplas?
    • Learn about Octaplas
  • Benefits of octaplas
    • Ensure Bag-to-Bag Consistency
    • Pathogen Safety
    • Optimized Production Process
    • Minimize Risk of Transfusion Related Reactions
  • Efficacy & Safety
    • Cardiac Surgery
    • Liver Disease and Liver Transplantation
    • Thrombotic Thrombocytopenic Purpura (TTP)
    • Pediatric Patients
  • Dosing & Administration
    • Dosage and Administration
    • Storage and Handling
  • Connect
    • How to Order
    • Find a Rep
  • Intended for US Healthcare Professionals Only

Octaplas Sitemap

Home / Site Map

Pages

  • Home
  • What is octaplas?
  • Benefits of octaplas
    • Pathogen Safety
    • Optimized Production Process
    • Minimize Risk of Transfusion Related Reactions
  • Efficacy & Safety
    • Liver Disease and Liver Transplantation
    • Thrombotic Thrombocytopenic Purpura (TTP)
    • Pediatric Patients
  • Dosing & Administration
    • Storage and Handling
  • Connect
    • Find a Rep
  • Contact Us
  • Site Map
  • Important Safety Information
Indications and Important Safety Information for octaplas®, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion

Please see octaplas full Prescribing Information.

Indications and Important Safety Information for octaplas®, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion

Please see octaplas full Prescribing Information.

Indications and Usage

Octaplas® is a solvent/detergent (S/D) treated, pooled human plasma indicated for replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or who are undergoing cardiac surgery or liver transplantation; and plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

Contraindications

Octaplas is contraindicated in patients with immunoglobulin A (IgA) deficiency; severe deficiency of protein S; history of hypersensitivity to fresh frozen plasma or to plasma-derived products including any plasma protein; or a history of hypersensitivity reaction to octaplas.

Warnings and Precautions

Transfusion reactions can occur with ABO blood group mismatches. Administration of octaplas must be based on ABO-blood group compatibility. High infusion rates can induce hypervolemia with consequent pulmonary edema or cardiac failure. Excessive bleeding due to hyperfibrinolysis can occur due to low levels of alpha2-antiplasmin (also named plasmin inhibitor). Thrombosis can occur due to low levels of Protein S. Citrate toxicity can occur with volumes exceeding one milliliter of octaplas per kg per minute. octaplas is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Adverse Reactions

The most common adverse reactions observed in ≥ 1% of patients included pruritus, urticaria, nausea, headache, paresthesia. Serious adverse reactions seen in clinical trials were anaphylactic shock, citrate toxicity and severe hypotension.

Please see octaplas full Prescribing Information

Scroll Back to Top
Octapharma logo
  • Home
  • Site Map
  • Terms of Use
  • Privacy Policy
  • California Required Statements
  • Contact Us
© 2025 Octapharma USA Inc. All Rights Reserved
  • About Octapharma
  • OPLAS-0159

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs)

This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our privacy policy for more details.